JP2010518026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518026A5 JP2010518026A5 JP2009548501A JP2009548501A JP2010518026A5 JP 2010518026 A5 JP2010518026 A5 JP 2010518026A5 JP 2009548501 A JP2009548501 A JP 2009548501A JP 2009548501 A JP2009548501 A JP 2009548501A JP 2010518026 A5 JP2010518026 A5 JP 2010518026A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- heteroaryl
- heterocyclyl
- haloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 228
- 125000001188 haloalkyl group Chemical group 0.000 claims description 228
- 125000001072 heteroaryl group Chemical group 0.000 claims description 227
- 125000000623 heterocyclic group Chemical group 0.000 claims description 226
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 218
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 212
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 202
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 201
- 229910052739 hydrogen Inorganic materials 0.000 claims description 156
- 239000001257 hydrogen Substances 0.000 claims description 156
- 150000002431 hydrogen Chemical class 0.000 claims description 152
- 125000003342 alkenyl group Chemical group 0.000 claims description 140
- 125000003118 aryl group Chemical group 0.000 claims description 138
- 125000000304 alkynyl group Chemical group 0.000 claims description 126
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 121
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 108
- 125000001475 halogen functional group Chemical group 0.000 claims description 104
- 125000002947 alkylene group Chemical group 0.000 claims description 100
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 100
- 125000003107 substituted aryl group Chemical group 0.000 claims description 96
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 90
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims description 90
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims description 90
- -1 heterocyclylalkynyl Chemical group 0.000 claims description 90
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 78
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 claims description 72
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 72
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 72
- 150000001875 compounds Chemical class 0.000 claims description 64
- 125000001424 substituent group Chemical group 0.000 claims description 55
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 54
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 54
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 54
- 125000004450 alkenylene group Chemical group 0.000 claims description 36
- 125000004419 alkynylene group Chemical group 0.000 claims description 36
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 29
- 208000002193 Pain Diseases 0.000 claims description 28
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 8
- 125000001041 indolyl group Chemical group 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 4
- GQTHJKCHZISVJO-UHFFFAOYSA-N 3-[4-(2-butyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)anilino]pyrrolidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 GQTHJKCHZISVJO-UHFFFAOYSA-N 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 210000000578 peripheral nerve Anatomy 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 108010052164 Sodium Channels Proteins 0.000 claims description 3
- 102000018674 Sodium Channels Human genes 0.000 claims description 3
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims description 3
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- BDNGJSYVQWBMMY-LJQANCHMSA-N 2-(2-cyclopropylethyl)-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound N1=C2C=CC=CN2C(=O)C(C=2C=CC(N[C@H]3CNCC3)=CC=2)=C1CCC1CC1 BDNGJSYVQWBMMY-LJQANCHMSA-N 0.000 claims description 2
- CGRSWHYBXCGJKQ-LJQANCHMSA-N 2-(3-methylbutyl)-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)CCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 CGRSWHYBXCGJKQ-LJQANCHMSA-N 0.000 claims description 2
- UGULKPLSXNNWLT-UHFFFAOYSA-N 2-(propan-2-ylamino)-3-[4-(pyrrolidin-3-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)NC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCNC1 UGULKPLSXNNWLT-UHFFFAOYSA-N 0.000 claims description 2
- UGULKPLSXNNWLT-QGZVFWFLSA-N 2-(propan-2-ylamino)-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)NC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 UGULKPLSXNNWLT-QGZVFWFLSA-N 0.000 claims description 2
- MEWSBWPKBQRBSI-UHFFFAOYSA-N 2-(propylamino)-3-[4-(pyrrolidin-3-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCNC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCNC1 MEWSBWPKBQRBSI-UHFFFAOYSA-N 0.000 claims description 2
- OHEBENJHYVXWQU-UHFFFAOYSA-N 2-[[4-(2-butyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)phenyl]carbamoyl]pyrrolidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC(=O)C1CCCN1C(O)=O OHEBENJHYVXWQU-UHFFFAOYSA-N 0.000 claims description 2
- WILSLAKCHWCKBA-UHFFFAOYSA-N 2-butyl-3-(1-pyrrolidin-3-yl-2,3-dihydroindol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1CC2)=CC=C1N2C1CCNC1 WILSLAKCHWCKBA-UHFFFAOYSA-N 0.000 claims description 2
- LZGWVSQVIMHLMP-UHFFFAOYSA-N 2-butyl-3-(1h-indol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=C2NC=CC2=CC(C=2C(=O)N3C=CC=CC3=NC=2CCCC)=C1 LZGWVSQVIMHLMP-UHFFFAOYSA-N 0.000 claims description 2
- PBJYXCASMFAEIC-UHFFFAOYSA-N 2-butyl-3-(2,3-dihydro-1h-indol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=C2NCCC2=CC(C=2C(=O)N3C=CC=CC3=NC=2CCCC)=C1 PBJYXCASMFAEIC-UHFFFAOYSA-N 0.000 claims description 2
- FTAAYXQDBYHHAI-UHFFFAOYSA-N 2-butyl-3-(2-chlorophenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=CC=C1Cl FTAAYXQDBYHHAI-UHFFFAOYSA-N 0.000 claims description 2
- YRLFNLXYTSJOOE-UHFFFAOYSA-N 2-butyl-3-(3-chloro-4-methoxyphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(OC)C(Cl)=C1 YRLFNLXYTSJOOE-UHFFFAOYSA-N 0.000 claims description 2
- UFANQXDTXYHRHA-UHFFFAOYSA-N 2-butyl-3-(3-chlorophenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=CC(Cl)=C1 UFANQXDTXYHRHA-UHFFFAOYSA-N 0.000 claims description 2
- OMEVOAPWXAAPAA-UHFFFAOYSA-N 2-butyl-3-(4-chloro-2-methylphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1C OMEVOAPWXAAPAA-UHFFFAOYSA-N 0.000 claims description 2
- AXZGRDUIRBJSFW-UHFFFAOYSA-N 2-butyl-3-(4-chloro-3-fluorophenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C(F)=C1 AXZGRDUIRBJSFW-UHFFFAOYSA-N 0.000 claims description 2
- HEQFGZGSYXGNRC-UHFFFAOYSA-N 2-butyl-3-(4-chloro-3-methylphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C(C)=C1 HEQFGZGSYXGNRC-UHFFFAOYSA-N 0.000 claims description 2
- WJINBXRGUDWNAD-UHFFFAOYSA-N 2-butyl-3-(4-chlorophenyl)-7-fluoropyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC(F)=CN2C(=O)C=1C1=CC=C(Cl)C=C1 WJINBXRGUDWNAD-UHFFFAOYSA-N 0.000 claims description 2
- GZLWCMCIQCGIBW-UHFFFAOYSA-N 2-butyl-3-(4-chlorophenyl)-7-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC(C)=CN2C(=O)C=1C1=CC=C(Cl)C=C1 GZLWCMCIQCGIBW-UHFFFAOYSA-N 0.000 claims description 2
- YTBASMOHBHHWDW-UHFFFAOYSA-N 2-butyl-3-(4-chlorophenyl)-8-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=C(C(F)(F)F)C=CN2C(=O)C=1C1=CC=C(Cl)C=C1 YTBASMOHBHHWDW-UHFFFAOYSA-N 0.000 claims description 2
- KGTOIPOLSLXEJA-UHFFFAOYSA-N 2-butyl-3-(4-chlorophenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 KGTOIPOLSLXEJA-UHFFFAOYSA-N 0.000 claims description 2
- YVSWUEUANBKTRA-UHFFFAOYSA-N 2-butyl-3-(4-chlorophenyl)pyrimido[2,1-a]isoquinolin-4-one Chemical compound CCCCC=1N=C2C3=CC=CC=C3C=CN2C(=O)C=1C1=CC=C(Cl)C=C1 YVSWUEUANBKTRA-UHFFFAOYSA-N 0.000 claims description 2
- NDKPIIGWKYOUTI-UHFFFAOYSA-N 2-butyl-3-(4-hydroxyphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(O)C=C1 NDKPIIGWKYOUTI-UHFFFAOYSA-N 0.000 claims description 2
- XAHBUOXGWYENNJ-UHFFFAOYSA-N 2-butyl-3-(4-methoxyphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(OC)C=C1 XAHBUOXGWYENNJ-UHFFFAOYSA-N 0.000 claims description 2
- DHYAFPKQKHKPES-UHFFFAOYSA-N 2-butyl-3-(4-morpholin-4-ylphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N1CCOCC1 DHYAFPKQKHKPES-UHFFFAOYSA-N 0.000 claims description 2
- UUJWGBLOQFFVFN-UHFFFAOYSA-N 2-butyl-3-(6-chloropyridin-3-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)N=C1 UUJWGBLOQFFVFN-UHFFFAOYSA-N 0.000 claims description 2
- WEWHNKFNEFBMSV-UHFFFAOYSA-N 2-butyl-3-(6-piperazin-1-ylpyridin-3-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=N1)=CC=C1N1CCNCC1 WEWHNKFNEFBMSV-UHFFFAOYSA-N 0.000 claims description 2
- VPCREMHCSDZXBF-GOSISDBHSA-N 2-butyl-3-[2-methyl-4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C(=C1)C)=CC=C1N[C@@H]1CCNC1 VPCREMHCSDZXBF-GOSISDBHSA-N 0.000 claims description 2
- HZEUEQMTNNCZHI-UHFFFAOYSA-N 2-butyl-3-[3-(pyrrolidin-3-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=1)=CC=CC=1NC1CCNC1 HZEUEQMTNNCZHI-UHFFFAOYSA-N 0.000 claims description 2
- OYMFFFAKPOXNIA-UHFFFAOYSA-N 2-butyl-3-[4-(oxan-4-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCOCC1 OYMFFFAKPOXNIA-UHFFFAOYSA-N 0.000 claims description 2
- VRWTUXADFWUGHR-UHFFFAOYSA-N 2-butyl-3-[4-(piperidin-3-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCCNC1 VRWTUXADFWUGHR-UHFFFAOYSA-N 0.000 claims description 2
- DRFOQORPLGCOSD-UHFFFAOYSA-N 2-butyl-3-[4-(piperidin-4-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCNCC1 DRFOQORPLGCOSD-UHFFFAOYSA-N 0.000 claims description 2
- XQDNVUXVLJSPQO-UHFFFAOYSA-N 2-butyl-3-[4-(pyrrolidin-3-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCNC1 XQDNVUXVLJSPQO-UHFFFAOYSA-N 0.000 claims description 2
- MOOYRGXNSSBKMI-GOSISDBHSA-N 2-butyl-3-[4-[(3r)-pyrrolidin-3-yl]oxyphenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1O[C@@H]1CCNC1 MOOYRGXNSSBKMI-GOSISDBHSA-N 0.000 claims description 2
- YQVMONANQKRRNN-LJQANCHMSA-N 2-butyl-3-[4-[[(2r)-oxolan-2-yl]methylamino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC[C@H]1CCCO1 YQVMONANQKRRNN-LJQANCHMSA-N 0.000 claims description 2
- YQVMONANQKRRNN-IBGZPJMESA-N 2-butyl-3-[4-[[(2s)-oxolan-2-yl]methylamino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC[C@@H]1CCCO1 YQVMONANQKRRNN-IBGZPJMESA-N 0.000 claims description 2
- LFZITLDVTCNZHL-LJQANCHMSA-N 2-butyl-3-[4-[[(3r)-1-methylpyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCN(C)C1 LFZITLDVTCNZHL-LJQANCHMSA-N 0.000 claims description 2
- MSVAZTNPMCRPJD-GMUIIQOCSA-N 2-butyl-3-[4-[[(3r)-oxolan-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one;hydrochloride Chemical compound Cl.CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCOC1 MSVAZTNPMCRPJD-GMUIIQOCSA-N 0.000 claims description 2
- VRWTUXADFWUGHR-LJQANCHMSA-N 2-butyl-3-[4-[[(3r)-piperidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCCNC1 VRWTUXADFWUGHR-LJQANCHMSA-N 0.000 claims description 2
- ZKXJCNSOTJAVJK-GOSISDBHSA-N 2-butyl-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]-8-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=C(C(F)(F)F)C=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 ZKXJCNSOTJAVJK-GOSISDBHSA-N 0.000 claims description 2
- XQDNVUXVLJSPQO-GOSISDBHSA-N 2-butyl-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 XQDNVUXVLJSPQO-GOSISDBHSA-N 0.000 claims description 2
- DMGZGGQSZWVQDP-OAQYLSRUSA-N 2-butyl-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrimido[2,1-a]isoquinolin-4-one Chemical compound CCCCC=1N=C2C3=CC=CC=C3C=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 DMGZGGQSZWVQDP-OAQYLSRUSA-N 0.000 claims description 2
- XQDNVUXVLJSPQO-SFHVURJKSA-N 2-butyl-3-[4-[[(3s)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@H]1CCNC1 XQDNVUXVLJSPQO-SFHVURJKSA-N 0.000 claims description 2
- AOCDPQJHJRDOIP-HXUWFJFHSA-N 2-butyl-3-[4-[methyl-[(3r)-1-methylpyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N(C)[C@@H]1CCN(C)C1 AOCDPQJHJRDOIP-HXUWFJFHSA-N 0.000 claims description 2
- YVCXJLUADGVPCO-UHFFFAOYSA-N 2-butyl-3-[4-chloro-3-(trifluoromethyl)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C(C(F)(F)F)=C1 YVCXJLUADGVPCO-UHFFFAOYSA-N 0.000 claims description 2
- UUFSNKDLAKYBCK-UHFFFAOYSA-N 2-butyl-7-chloro-3-(4-hydroxyphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC(Cl)=CN2C(=O)C=1C1=CC=C(O)C=C1 UUFSNKDLAKYBCK-UHFFFAOYSA-N 0.000 claims description 2
- OAYCSEAHQYXYTQ-UHFFFAOYSA-N 2-butyl-7-chloro-3-(4-methoxyphenyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC(Cl)=CN2C(=O)C=1C1=CC=C(OC)C=C1 OAYCSEAHQYXYTQ-UHFFFAOYSA-N 0.000 claims description 2
- DUNNCDGYFQXOOO-GOSISDBHSA-N 2-butyl-7-fluoro-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC(F)=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 DUNNCDGYFQXOOO-GOSISDBHSA-N 0.000 claims description 2
- YCOATZUSCXVMMO-LJQANCHMSA-N 2-butyl-7-methyl-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC(C)=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 YCOATZUSCXVMMO-LJQANCHMSA-N 0.000 claims description 2
- VTPMWGPEFFBIEX-MRXNPFEDSA-N 2-ethyl-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 VTPMWGPEFFBIEX-MRXNPFEDSA-N 0.000 claims description 2
- RZUPNGPKGQQTJZ-UHFFFAOYSA-N 2-methoxy-3-[4-(pyrrolidin-3-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound COC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCNC1 RZUPNGPKGQQTJZ-UHFFFAOYSA-N 0.000 claims description 2
- CSSBPAYOUNIHDV-MRXNPFEDSA-N 2-methyl-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 CSSBPAYOUNIHDV-MRXNPFEDSA-N 0.000 claims description 2
- HKYVBLRNTTZKKP-UHFFFAOYSA-N 2-propan-2-yl-3-[4-(pyrrolidin-3-ylamino)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCNC1 HKYVBLRNTTZKKP-UHFFFAOYSA-N 0.000 claims description 2
- YSEKBRHKZLIILB-QGZVFWFLSA-N 2-propoxy-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCOC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 YSEKBRHKZLIILB-QGZVFWFLSA-N 0.000 claims description 2
- SUBUNEHCJJBWIV-GOSISDBHSA-N 2-pyrrolidin-1-yl-3-[4-[[(3r)-pyrrolidin-3-yl]amino]phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1CCCN1C=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1N[C@@H]1CCNC1 SUBUNEHCJJBWIV-GOSISDBHSA-N 0.000 claims description 2
- FIYBEHLETGRDHT-UHFFFAOYSA-N 3-(4-aminophenyl)-2-butylpyrido[1,2-a]pyrimidin-4-one Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(N)C=C1 FIYBEHLETGRDHT-UHFFFAOYSA-N 0.000 claims description 2
- UGZDQGBOJQNIOI-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(2-cyclopropylethyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1C(C(N1C=CC=CC1=N1)=O)=C1CCC1CC1 UGZDQGBOJQNIOI-UHFFFAOYSA-N 0.000 claims description 2
- XMHYGYPVHNFOHG-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(2-methoxyethyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound COCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 XMHYGYPVHNFOHG-UHFFFAOYSA-N 0.000 claims description 2
- ZPWKLPQWFVNZPA-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(3-methylbutyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)CCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 ZPWKLPQWFVNZPA-UHFFFAOYSA-N 0.000 claims description 2
- DWCXLAYPIWFMAY-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(propan-2-ylamino)pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)NC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 DWCXLAYPIWFMAY-UHFFFAOYSA-N 0.000 claims description 2
- HUMWKONUQCTUBU-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(propylamino)pyrido[1,2-a]pyrimidin-4-one Chemical compound CCCNC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 HUMWKONUQCTUBU-UHFFFAOYSA-N 0.000 claims description 2
- YCAFOCCLIJNDQW-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one Chemical compound FC(F)(F)C=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 YCAFOCCLIJNDQW-UHFFFAOYSA-N 0.000 claims description 2
- RNMUPOPWKPMVST-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-ethylpyrido[1,2-a]pyrimidin-4-one Chemical compound CCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 RNMUPOPWKPMVST-UHFFFAOYSA-N 0.000 claims description 2
- SDVATPHLGJKODD-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-methoxypyrido[1,2-a]pyrimidin-4-one Chemical compound COC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 SDVATPHLGJKODD-UHFFFAOYSA-N 0.000 claims description 2
- KEHFSHONMLISJL-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound CC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 KEHFSHONMLISJL-UHFFFAOYSA-N 0.000 claims description 2
- NLHYVZDXRIESOZ-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-propan-2-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 NLHYVZDXRIESOZ-UHFFFAOYSA-N 0.000 claims description 2
- QRIHSFIKJPZJOU-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-propoxypyrido[1,2-a]pyrimidin-4-one Chemical compound CCCOC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 QRIHSFIKJPZJOU-UHFFFAOYSA-N 0.000 claims description 2
- DDRZRISWLVNWSX-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-propylpyrido[1,2-a]pyrimidin-4-one Chemical compound CCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(Cl)C=C1 DDRZRISWLVNWSX-UHFFFAOYSA-N 0.000 claims description 2
- STYXGPBKXFJQBU-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-pyrrolidin-1-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1C(C1=O)=C(N2CCCC2)N=C2N1C=CC=C2 STYXGPBKXFJQBU-UHFFFAOYSA-N 0.000 claims description 2
- DEZGIDKUELDDCQ-UHFFFAOYSA-N 3-[4-(2-butyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)-2-fluoroanilino]pyrrolidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1F)=CC=C1NC1CCN(C(O)=O)C1 DEZGIDKUELDDCQ-UHFFFAOYSA-N 0.000 claims description 2
- RIAFLGPZYMYIIF-UHFFFAOYSA-N 3-[4-(2-butyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)-3-methylanilino]pyrrolidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C(=C1)C)=CC=C1NC1CCN(C(O)=O)C1 RIAFLGPZYMYIIF-UHFFFAOYSA-N 0.000 claims description 2
- NYKVRZGEBDPSMF-UHFFFAOYSA-N 3-[4-(2-butyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)anilino]piperidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCCN(C(O)=O)C1 NYKVRZGEBDPSMF-UHFFFAOYSA-N 0.000 claims description 2
- PPVQKMTVPSFXLT-UHFFFAOYSA-N 3-[4-(2-butyl-4-oxopyrimido[2,1-a]isoquinolin-3-yl)anilino]pyrrolidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C3=CC=CC=C3C=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 PPVQKMTVPSFXLT-UHFFFAOYSA-N 0.000 claims description 2
- HWLAFAZBLSKSIY-UHFFFAOYSA-N 3-[4-(2-ethyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)anilino]pyrrolidine-1-carboxylic acid Chemical compound CCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 HWLAFAZBLSKSIY-UHFFFAOYSA-N 0.000 claims description 2
- WASLUYKIXSJHQJ-UHFFFAOYSA-N 3-[4-(2-methyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)anilino]pyrrolidine-1-carboxylic acid Chemical compound CC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 WASLUYKIXSJHQJ-UHFFFAOYSA-N 0.000 claims description 2
- PDGATHLJWHVELV-UHFFFAOYSA-N 3-[4-(4-oxo-2-propoxypyrido[1,2-a]pyrimidin-3-yl)anilino]pyrrolidine-1-carboxylic acid Chemical compound CCCOC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 PDGATHLJWHVELV-UHFFFAOYSA-N 0.000 claims description 2
- HATAAZIFHFGNAM-UHFFFAOYSA-N 3-[4-(4-oxo-2-propylpyrido[1,2-a]pyrimidin-3-yl)anilino]pyrrolidine-1-carboxylic acid Chemical compound CCCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 HATAAZIFHFGNAM-UHFFFAOYSA-N 0.000 claims description 2
- LGVCGKJWFRDWEQ-UHFFFAOYSA-N 3-[4-(4-oxo-2-pyrrolidin-1-ylpyrido[1,2-a]pyrimidin-3-yl)anilino]pyrrolidine-1-carboxylic acid Chemical compound C1N(C(=O)O)CCC1NC1=CC=C(C=2C(N3C=CC=CC3=NC=2N2CCCC2)=O)C=C1 LGVCGKJWFRDWEQ-UHFFFAOYSA-N 0.000 claims description 2
- YQMJPUMZGVLRBN-UHFFFAOYSA-N 3-[4-[2-(2-cyclopropylethyl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]anilino]pyrrolidine-1-carboxylic acid Chemical compound C1N(C(=O)O)CCC1NC1=CC=C(C=2C(N3C=CC=CC3=NC=2CCC2CC2)=O)C=C1 YQMJPUMZGVLRBN-UHFFFAOYSA-N 0.000 claims description 2
- GHLPOPZJDPCJPI-UHFFFAOYSA-N 3-[4-[2-(3-methylbutyl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]anilino]pyrrolidine-1-carboxylic acid Chemical compound CC(C)CCC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 GHLPOPZJDPCJPI-UHFFFAOYSA-N 0.000 claims description 2
- QEUWOGCXYLAJAF-UHFFFAOYSA-N 3-[4-[2-butyl-4-oxo-8-(trifluoromethyl)pyrido[1,2-a]pyrimidin-3-yl]anilino]pyrrolidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C=C(C(F)(F)F)C=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 QEUWOGCXYLAJAF-UHFFFAOYSA-N 0.000 claims description 2
- DGOXHXVVQKDAND-UHFFFAOYSA-N 3-[4-[4-oxo-2-(propan-2-ylamino)pyrido[1,2-a]pyrimidin-3-yl]anilino]pyrrolidine-1-carboxylic acid Chemical compound CC(C)NC=1N=C2C=CC=CN2C(=O)C=1C(C=C1)=CC=C1NC1CCN(C(O)=O)C1 DGOXHXVVQKDAND-UHFFFAOYSA-N 0.000 claims description 2
- SOWSUIUXEKYCCK-UHFFFAOYSA-N 3-[[5-(2-butyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)pyridin-2-yl]amino]pyrrolidine-1-carboxylic acid Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C(C=N1)=CC=C1NC1CCN(C(O)=O)C1 SOWSUIUXEKYCCK-UHFFFAOYSA-N 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010020844 Hyperthermia malignant Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000007914 Labor Pain Diseases 0.000 claims description 2
- 208000035945 Labour pain Diseases 0.000 claims description 2
- 208000026709 Liddle syndrome Diseases 0.000 claims description 2
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 2
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010037113 Pseudoaldosteronism Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 206010038743 Restlessness Diseases 0.000 claims description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 claims description 2
- 206010049447 Tachyarrhythmia Diseases 0.000 claims description 2
- 208000001871 Tachycardia Diseases 0.000 claims description 2
- 206010057040 Temperature intolerance Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- FIZOHFYFXDSGFI-UHFFFAOYSA-N [4-(2-butyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)phenyl] trifluoromethanesulfonate Chemical compound CCCCC=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1 FIZOHFYFXDSGFI-UHFFFAOYSA-N 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000025307 bipolar depression Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000035606 childbirth Effects 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000008543 heat sensitivity Effects 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 201000007004 malignant hyperthermia Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 230000000324 neuroprotective effect Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000019865 paroxysmal extreme pain disease Diseases 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 0 *C1=C(*)N=C(C=CC=C2)N2C1=O Chemical compound *C1=C(*)N=C(C=CC=C2)N2C1=O 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88825307P | 2007-02-05 | 2007-02-05 | |
| US91212207P | 2007-04-16 | 2007-04-16 | |
| PCT/US2008/053075 WO2008097991A1 (en) | 2007-02-05 | 2008-02-05 | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518026A JP2010518026A (ja) | 2010-05-27 |
| JP2010518026A5 true JP2010518026A5 (en:Method) | 2012-04-12 |
Family
ID=39420569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548501A Withdrawn JP2010518026A (ja) | 2007-02-05 | 2008-02-05 | ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080194616A1 (en:Method) |
| EP (1) | EP2079737A1 (en:Method) |
| JP (1) | JP2010518026A (en:Method) |
| AR (1) | AR065194A1 (en:Method) |
| AU (1) | AU2008213836A1 (en:Method) |
| BR (1) | BRPI0807351A2 (en:Method) |
| CA (1) | CA2677493A1 (en:Method) |
| CL (1) | CL2008000369A1 (en:Method) |
| MX (1) | MX2009008338A (en:Method) |
| RU (1) | RU2009133336A (en:Method) |
| TW (1) | TW200838539A (en:Method) |
| WO (1) | WO2008097991A1 (en:Method) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009006507A (es) * | 2006-12-18 | 2009-08-18 | Cardoz Ab | Nueva combinacion para usarse en el tratamiento de trastornos inflamatorios. |
| ES2395120T3 (es) * | 2006-12-20 | 2013-02-08 | Cardoz Ab | Combinación de pemirolast y ramotrobán para su uso en el tratamiento de transtornos inflamatorios |
| AU2009220825A1 (en) * | 2008-01-11 | 2012-01-19 | Glenmark Pharmaceuticals, S.A. | Fused pyrimidine derivatives as TRPV3 modulators |
| CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| EP2303251B1 (en) * | 2008-04-07 | 2012-05-16 | Cardoz AB | New combination for use in the treatment of inflammatory disorders |
| US8119647B2 (en) * | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| CN101628913B (zh) * | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| DK2448938T5 (en) | 2009-06-29 | 2015-10-05 | Incyte Corp | Pyrimidinones AS PI3K inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| WO2012007836A1 (en) | 2010-07-16 | 2012-01-19 | Purdue Pharma .Lp. | Pyridine compounds as sodium channel blockers |
| AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| HRP20170285T1 (hr) | 2011-09-02 | 2017-04-21 | Incyte Holdings Corporation | Heterociklilamini kao inhibitori pi3k |
| BR112014010271A2 (pt) | 2011-10-31 | 2017-04-18 | Xenon Pharmaceuticals Inc | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| WO2013115884A2 (en) * | 2011-11-15 | 2013-08-08 | Trustees Of Boston University | Pyridopyrimidinone inhibitors of viruses |
| AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| AR091112A1 (es) * | 2012-05-22 | 2015-01-14 | Genentech Inc | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 |
| CA2878478A1 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| EP2970156B1 (en) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| CN105611923B (zh) * | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| AU2014356967A1 (en) | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| MX373232B (es) | 2015-02-27 | 2020-05-08 | Incyte Holdings Corp | Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación. |
| WO2016166078A1 (en) * | 2015-04-15 | 2016-10-20 | F. Hoffmann-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| NZ737536A (en) | 2015-05-22 | 2019-04-26 | Genentech Inc | Substituted benzamides and methods of use thereof |
| ES2821049T3 (es) * | 2015-06-18 | 2021-04-23 | 89Bio Ltd | Derivados de piperidina 1,4 sustituidos |
| US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| MX386501B (es) | 2015-09-28 | 2025-03-19 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| WO2019165290A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| MX2020012826A (es) | 2018-06-01 | 2021-03-09 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |
| WO2019236694A1 (en) * | 2018-06-05 | 2019-12-12 | Incarda Therapeutics, Inc. | Methods for diagnosing brugada syndrome using an aerosol |
| US12473289B2 (en) * | 2019-11-25 | 2025-11-18 | Amgen Inc. | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
| CN110818709B (zh) * | 2019-11-28 | 2022-09-02 | 成都大学 | 一种co2参与下合成嘧啶酮类化合物的方法 |
| CN113292557B (zh) * | 2021-05-31 | 2022-02-11 | 贵州大学 | 一种含吲哚单元的吡啶并嘧啶酮类介离子衍生物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63112566A (ja) * | 1986-10-28 | 1988-05-17 | Nissan Chem Ind Ltd | ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤 |
| US20070213338A1 (en) * | 2003-10-21 | 2007-09-13 | Lebsack Alec D | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain |
| AR053713A1 (es) * | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| JP2008546843A (ja) * | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
| AU2006299042B8 (en) * | 2005-10-04 | 2011-09-15 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | HIV integrase inhibitors |
| EP1818058A3 (en) * | 2006-02-13 | 2007-11-07 | Astion Pharma A/S | Treatment of mmp-mediated dermatological diseases with pemirolast |
-
2008
- 2008-02-05 TW TW097104675A patent/TW200838539A/zh unknown
- 2008-02-05 MX MX2009008338A patent/MX2009008338A/es unknown
- 2008-02-05 AU AU2008213836A patent/AU2008213836A1/en not_active Abandoned
- 2008-02-05 AR ARP080100493A patent/AR065194A1/es unknown
- 2008-02-05 CA CA002677493A patent/CA2677493A1/en not_active Abandoned
- 2008-02-05 RU RU2009133336/04A patent/RU2009133336A/ru unknown
- 2008-02-05 JP JP2009548501A patent/JP2010518026A/ja not_active Withdrawn
- 2008-02-05 BR BRPI0807351-1A patent/BRPI0807351A2/pt not_active IP Right Cessation
- 2008-02-05 EP EP08729067A patent/EP2079737A1/en not_active Withdrawn
- 2008-02-05 WO PCT/US2008/053075 patent/WO2008097991A1/en not_active Ceased
- 2008-02-05 US US12/026,435 patent/US20080194616A1/en not_active Abandoned
- 2008-02-05 CL CL200800369A patent/CL2008000369A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518026A5 (en:Method) | ||
| RU2009133336A (ru) | Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами | |
| US10604504B2 (en) | Indole carboxamide compounds | |
| AU2016276806B2 (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| KR101877189B1 (ko) | Jak 억제제로서의 아미노피리미디닐 화합물 | |
| US9815832B2 (en) | Azabenzimidazole compounds | |
| EP2444399B1 (en) | Oxadiazole derivatives and their use as metabotropic glutamate receptor -842 potentiators | |
| AU2015298378B2 (en) | Imidazopyridazine compounds | |
| JP2021533093A (ja) | モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物 | |
| JP2022536540A (ja) | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 | |
| WO2017195216A4 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors | |
| TW200911255A (en) | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 | |
| US12486274B2 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| US11541057B2 (en) | Thienopyrimidinone NMDA receptor modulators and uses thereof | |
| JP2022502370A (ja) | 置換ピリジニル化合物およびその使用 | |
| US20200123147A1 (en) | Thiazole compounds useful as prmt5 inhibitors | |
| JP2020531574A (ja) | 化合物、その医薬組成物及びその使用及び応用 | |
| JP7110338B2 (ja) | ムスカリンｍ１受容体陽性アロステリックモジュレーターである多環式アミド類 | |
| JP2022081710A (ja) | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 | |
| IL303320A (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| US20230348369A1 (en) | Nampt modulators | |
| US20230038929A1 (en) | Fused Tricyclic Heterocyclic Compounds and Uses Thereof | |
| CN111936488A (zh) | 用于治疗寄生虫感染的新颖化合物 | |
| HK40112327A (zh) | 用於治疗精神障碍的苯并异噻唑和苯并异恶唑化合物 | |
| KR20240144259A (ko) | 정신 장애 치료를 위한 벤조이소티아졸 및 벤조이속사졸 화합물 |